PRESS RELEASE – June 13, 2022 — Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) aka Johne’s disease that could save the New Zealand dairy industry upwards of $80m/year in lost production.
Bolstered By Investment, Pictor Partners with Mobility Health to Offer PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster $6.1 Million investment for Pictor — led by Marko Bogoievski and K One W One Ltd. — to aid the market development of novel antibody testing and other in vitro diagnostics PRESS RELEASE – April […]
Pictor Successfully Completes Validation Trial in U.S. for its SARS-Co-V-2 Antibody Test PRESS RELEASE – January 20, 2022 — New Zealand diagnostic biotech company Pictor Ltd. announced today that it has successfully completed validation trials at two separate sites in the United States, one of which was Florida-based Boca Biolistics, for its COVID-19 antibody test. The Pictor test […]
Pictor and SCIENION partner to commercialise high-throughput SARS-CoV-2 antibody testing system to support ongoing fight against pandemic The partnership will incorporate SCIENION’s CL2 sciREADER system into the PictArray SARS-CoV-2 Serology Test which will shortly begin clinical trials for FDA EUA market clearance PRESS RELEASE – September 29, 2021 — Auckland-based diagnostic biotech company Pictor has […]